GlobeImmune Announces Appointment of J. William Freytag, Ph.D to Its Board of Directors
| Source: GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - March 25, 2008) - GlobeImmune, Inc. announced today the
addition of J. William Freytag, Ph.D. to its Board of Directors.
"Dr. Freytag brings over 25 years of research, product development and
commercialization experience to the Board," said Timothy C. Rodell M.D.,
GlobeImmune's Chief Executive Officer. "His recent experience as Chairman
and CEO of Myogen and Aspreva Pharmaceuticals, biotechnology companies with
preclinical, clinical and sales and marketing capabilities, will be
invaluable to us as the company continues to grow."
Dr. Freytag was President, Chief Executive Officer and Chairman of the
Board of Aspreva Pharmaceuticals Company from July 2007 through December
2007 when Aspreva was acquired by Galenica for approximately $915 million.
He held the same positions with Myogen, Inc. from July 1998 until November
2006 when Myogen was acquired by Gilead Sciences for approximately $2.5
billion. Dr. Freytag currently serves on the Board of Directors for Sierra
Neuropharmaceuticals, ARCA Discovery, AlphaSniffer and Immunicon. Dr.
Freytag has held senior executive roles in a number of capacities at
companies such as Somatogen, Inc., a biopharmaceutical company where he was
responsible for corporate and commercial development and at Boehringer
Mannheim Corporation where he served as President of Research and
Development. Dr. Freytag spent 10 years with DuPont Medical Products in
various research and business positions. He earned his Ph.D. in
biochemistry from the University of Kansas Medical Center.
About GlobeImmune, Inc.
GlobeImmune is a private Colorado-based company developing active
immunotherapies called Tarmogens for the treatment of cancer and infectious
diseases. The Company's lead oncology program, GI-4000, is designed to be
a treatment for cancers of the lung and gastrointestinal tract. A
randomized, placebo-controlled phase 2 trial in patients with resectable
pancreas cancer in combination with adjuvant gemcitabine is ongoing. The
Company's lead infectious disease candidate, GI-5005, is a Tarmogen being
developed for the treatment of chronic hepatitis C infection. GI-5005 is
designed to complement both the current and emerging standard of care for
hepatitis C infection through the direct elimination of chronically
infected cells. A randomized phase 2 study of GI-5005 in combination with
standard of care for patients with chronic hepatitis C infection is
currently ongoing.
For additional information, please visit the company's website at
www.globeimmune.com